Waters Division President to Retire
Key Leaders Elevated, Focused on Key Products and Markets
These changes coincide with
“Art is to be congratulated on a long and successful nearly 40-year career devoted to advancing Waters’ industry-leading technologies and global reach, and we are grateful for his countless contributions to our success,” said O'Connell. “Our new executive team will enable us to drive our business forward with great continuity, and enhance our strategic and operational capability. I have high confidence in our experienced team to execute our growth plan, and to accelerate the introduction of meaningful new innovations to market."
Current members of the Executive Committee will play enhanced global functional leadership roles:
Mark T. Beaudouin, Senior Vice President, General Counsel and Secretary
Eugene G. Cassis, Senior Vice President and Chief Financial Officer
Elizabeth B. Rae, Senior Vice President, Global Human Resources
Five executives have been promoted to the Executive Committee:
Michael C. Harrington, Senior Vice President, Global Markets, responsible for global marketing, sales, and customer support operations.
Terrance P. Kelly, Senior Vice President and President, TA Instruments, responsible for thermal analysis and rheology business operations.
Rohit Khanna, Senior Vice President, Applied Technology, responsible for chemistry, informatics and service offerings.
Ian S. King, Senior Vice President, Instrument Technology, responsible for separations and mass spectrometry instrument platforms.
David A. Terricciano, Senior Vice President, Global Operations, responsible for global quality, manufacturing and supply chain operations.
Further commentary will be made during the Company’s conference call to
discuss full year 2015 financial results on
This release may contain “forward-looking” statements regarding future
results and events. For this purpose, any statements that are not
statements of historical fact may be deemed forward-looking statements.
Without limiting the foregoing, the words, “feels”, “believes”,
“anticipates”, “plans”, “expects”, “intends”, “suggests”, “appears”,
“estimates”, “projects”, and similar expressions, whether in the
negative or affirmative, are intended to identify forward-looking
statements. The Company’s actual future results may differ significantly
from the results discussed in the forward-looking statements within this
release for a variety of reasons, including and without limitation,
uncertainties relating to organizational/leadership transition plans;
foreign exchange rate fluctuations potentially affecting translation of
the Company’s future non-U.S. operating results; the impact on demand
among the Company’s various market sectors from economic, sovereign and
political uncertainties; fluctuations in expenditures by the Company’s
customers, in particular large pharmaceutical companies; introduction of
competing products by other companies and loss of market share;
pressures on prices from competitors and/or customers; regulatory,
economic and competitive obstacles to new product introductions; other
changes in demand from the effect of mergers and acquisitions by the
Company’s customers; increased regulatory burdens as the Company’s
business evolves, especially with respect to the